<div id="readability-page-1"><p>The Group has been carrying on transactions with Lepu Medical and its subsidiaries and/or associates pursuant to the 2025 Procurement Framework Agreement which constituted a continuing connected transaction of the Company under Chapter 14A of the Listing Rules. Given the 2025 Procurement Framework Agreement will expire on December 31, 2025 and it is expected that the Group will continue to enter into procurement transactions of a similar nature with Lepu Medical and/or its subsidiaries and/or associates thereafter, on November 28, 2025, the New Procurement Framework Agreement was entered into between the Company and Lepu Medical. Lepu Medical and/or its subsidiaries and/or associates (excluding the Group) will supply to the Group raw materials and supplementary materials for clinical trials, pharmaceutical products, biological sample test services for clinical trials, products for employee welfare and other services. Lepu Medical will enter into or will procure its subsidiaries and/or associates to enter into separate procurement agreements with the Group in respect of such underlying supply transactions, and such separate agreements shall comply with the provisions and principles set out in the New Procurement Framework Agreement.<br/> From January 1, 2026 to December 31, 2026 (both dates inclusive). The term of the New Procurement Framework Agreement can be renewed upon the parties ' agreement, and such renewal will be subject to the requirements of applicable laws and regulations, and rules of the relevant stock exchange on which the Shares are listed (including the Listing Rules). Any renewal will be subject to a new agreement to be entered into by the parties and each such extension period shall in no event exceed three years. The transactions contemplated under the New Procurement Framework Agreement shall be conducted on normal commercial terms. The actual costs and payment terms (including timing and method of payment) for such underlying procurement transactions shall be set out in such separate procurement agreements entered into between the Group and Lepu Medical and/or its subsidiaries and/or associates. In order to ensure that the terms of the transactions in respect of the procurement of products and services by the Group from Lepu Medical and/or its subsidiaries and/or associates are fair and reasonable and in line with market practices, and that the terms of the transactions will be no less favorable to the Group than the terms of the transactions between the Group and Independent Third Parties, the Group has adopted the following measures: (a) to maintain regular contact with the suppliers of the Group (including Lepu Medical and/or  its subsidiaries and/or associates) to keep abreast of market developments and the price trend of products and services; and (b) to assess, review and compare the quotations or proposals taking into account various factors  including quality, payment, flexibility and after-sales services to ensure that the proposed  transactions will be consistent with the general interest of the Group and the Shareholders as  a whole.</p></div>

乐普医疗

<p>乐普生物制药有限公司与乐普医疗科技有限公司签署了一项新的采购框架协议，协议有效期为 2026 年 1 月 1 日至 2026 年 12 月 31 日。该协议涉及原材料、药品及其他服务的供应。该协议可根据适用的法律法规进行续签。交易将按照正常商业条款进行，确保公平和市场一致性</p>

乐普生物制药有限公司与乐普医疗科技有限公司达成采购框架协议